RxDoctor Payments Data

Paula McKinnon

Nurse Practitioner · Minocqua, WINPI 1750830105

Payments from drug & device makers

$592in general payments, 2019–2025

Across 22 payments — averaging $26.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$159
  • Actelion Pharmaceuticals US, Inc.$110
  • Amgen$101
  • Novartis$66
  • Pfizer$60
  • Kiniksa Pharmaceuticals International, PLC$34
  • plus $63 from 3 others

What the payments were for

  • Food & beverage$48382%
  • Education$10918%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$592 in reported general payments places this provider in the 85th percentile of 3,478 nurse practitioner providers in Wisconsin.

See all nurse practitioner providers in Wisconsin

Medicare billing

Part B allowed, 2024
$56,673
Medicare patients
452
Services billed
642

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban135$151,779
JardianceEmpagliflozin68$57,449
XareltoRivaroxaban19$27,729
EntrestoSacubitril/Valsartan21$25,620
Metoprolol Succinate126$2,093
Potassium Chloride58$1,376
Dofetilide16$1,286
Atorvastatin Calcium120$999
Ranolazine ErRanolazine14$945
Rosuvastatin Calcium52$825
Flecainide Acetate20$779
Losartan Potassium105$779
Ezetimibe25$710
Spironolactone113$633
Furosemide108$621

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$60$151,779135 claims
Johnson & JohnsonXarelto$23$27,72919 claims
NovartisEntresto$66$25,62021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,478 nurse practitioner providers in Wisconsin.

Other nurse practitioner in Minocqua

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →